Home » Pfizer’s Bococizumab Yields Positive Results in Phase 3
Pfizer’s Bococizumab Yields Positive Results in Phase 3
Pfizer’s bococizumab soared in a second Phase 3 study, meeting its co-primary endpoints of reducing low-density lipoprotein cholesterol at 12 weeks compared with placebo.
The SPIRE-AI study assessed the PCSK9 inhibitor in 299 patients with hyperlipidemia or mixed dyslipidemia receiving statin therapy. SPIRE-AI is the second of six studies evaluating the candidate’s lipid-lowering capabilities.
Bococizumab is not approved in any country.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May